About CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.17 per share
Price / Book48.94
Return on Equity-115.80%
Return on Assets-70.25%
CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics Inc (NASDAQ:CBAY) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. During the same quarter in the previous year, the company earned ($0.25) EPS. View CymaBay Therapeutics' Earnings History.
When will CymaBay Therapeutics make its next earnings announcement?
Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2017?
9 analysts have issued 12 month price targets for CymaBay Therapeutics' stock. Their forecasts range from $12.00 to $16.00. On average, they expect CymaBay Therapeutics' share price to reach $14.50 in the next year. View Analyst Ratings for CymaBay Therapeutics.
What are Wall Street analysts saying about CymaBay Therapeutics stock?
Here are some recent quotes from research analysts about CymaBay Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Expanded and extended Phase 2 trial could sync with EASL and AASLD. On today’s 3Q17 results conference call, management noted that all patients in the initial 12-week period of the low-dose study have entered the extension phase. At a minimum, we view the commentary as good news from a safety and tolerability standpoint and we assume it unlikely that patients would remain on drug even if safe and tolerable if there is deemed to be no clinical benefit. Management noted that the data set will mature" with time and that 6-month data could become available in 1H18 and 12-month data in 2H18. We note that EASL is scheduled for April 11-15 in Paris and AASLD is scheduled for November 9-13, 2018 in San Francisco." (11/8/2017)
- 2. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (9/18/2017)
- 3. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
- 4. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)
Who are some of CymaBay Therapeutics' key competitors?
Some companies that are related to CymaBay Therapeutics include Alder BioPharmaceuticals (ALDR), Aclaris Therapeutics (ACRS), Akebia Therapeutics (AKBA), MacroGenics (MGNX), Adaptimmune Therapeutics (ADAP), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), Vanda Pharmaceuticals (VNDA), Aduro BioTech (ADRO), ZIOPHARM Oncology (ZIOP), Five Prime Therapeutics (FPRX), Axovant Sciences (AXON), GlycoMimetics (GLYC), G1 THERAPEUTICS (GTHX), Keryx Biopharmaceuticals (KERX), Clementia Pharmaceuticals (CMTA), Deciphera Pharmaceuticals (DCPH) and Uniqure (QURE).
Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the folowing people:
- Robert James Wills Ph.D., Chairman of the Board (Age 62)
- Sujal Shah, President, Chief Executive Officer (Age 42)
- Charles A McWherter Ph.D, Senior Vice President, Chief Scientific Officer (Age 62)
- Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer (Age 47)
- Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance (Age 44)
- Paul T. Quinlan, General Counsel, Corporate Secretary (Age 53)
- Pol F. Boudes M.D., Chief Medical Officer (Age 58)
- Robert Booth Ph.D., Director
- Caroline Loewy, Director
- Evan A. Stein M.D. Ph.D., Director
Who owns CymaBay Therapeutics stock?
CymaBay Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (5.36%), Abingworth LLP (3.52%), Citadel Advisors LLC (1.46%), EAM Investors LLC (1.36%), Omega Fund Management LLC (1,260,230.80%) and Iguana Healthcare Management LLC (0.57%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Kurt Von Emster, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.
Who sold CymaBay Therapeutics stock? Who is selling CymaBay Therapeutics stock?
CymaBay Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Abingworth LLP. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.
Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?
CymaBay Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Citadel Advisors LLC, EAM Investors LLC, Omega Fund Management LLC, Ameriprise Financial Inc., GSA Capital Partners LLP, Iguana Healthcare Management LLC and Bank of New York Mellon Corp. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.
How do I buy CymaBay Therapeutics stock?
Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CymaBay Therapeutics' stock price today?
One share of CymaBay Therapeutics stock can currently be purchased for approximately $8.32.
How big of a company is CymaBay Therapeutics?
CymaBay Therapeutics has a market capitalization of $364.95 million. The biopharmaceutical company earns $-26,670,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. CymaBay Therapeutics employs 22 workers across the globe.
How can I contact CymaBay Therapeutics?
CymaBay Therapeutics' mailing address is 7999 GATEWAY BLVD SUITE 130, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]
MarketBeat Community Rating for CymaBay Therapeutics (CBAY)MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
CymaBay Therapeutics (NASDAQ:CBAY) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$14.50||$14.00||$13.71||$6.75|
|Price Target Upside: ||68.80% upside||68.07% upside||116.66% upside||61.10% upside|
CymaBay Therapeutics (NASDAQ:CBAY) Consensus Price Target History
CymaBay Therapeutics (NASDAQ:CBAY) Analyst Ratings History
(Data available from 12/17/2015 forward)
CymaBay Therapeutics (NASDAQ:CBAY) Earnings History and Estimates Chart
CymaBay Therapeutics (NASDAQ CBAY) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/22/2018|| || || || || || || || |
|11/8/2017||Q3 2017||($0.19)||($0.21)||$9.50 million||View||N/A|
|5/11/2017||Q1 2017||($0.27)||($0.20)||$4.79 million||View||N/A|
CymaBay Therapeutics (NASDAQ:CBAY) Earnings Estimates
2017 EPS Consensus Estimate: ($0.87)
2018 EPS Consensus Estimate: ($0.53)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by MarketBeat.com
CymaBay Therapeutics (NASDAQ CBAY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 69.12%
CymaBay Therapeutics (NASDAQ CBAY) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/10/2017||Kurt Von Emster||Director||Sell||50,048||$9.26||$463,444.48|| |
|11/2/2017||Carl Goldfischer||Director||Sell||18,000||$8.66||$155,880.00|| |
|11/2/2017||Charles Mcwherter||SVP||Buy||5,000||$8.67||$43,350.00|| |
|10/31/2017||Kurt Von Emster||Director||Sell||59,209||$9.27||$548,867.43|| |
|10/3/2017||Kurt Von Emster||Director||Sell||108,876||$7.85||$854,676.60|| |
|9/29/2017||Kurt Von Emster||Director||Sell||211,124||$8.09||$1,707,993.16|| |
|8/1/2017||Robert James Wills||Director||Buy||5,000||$6.84||$34,200.00|| |
|7/20/2017||Charles Mcwherter||SVP||Buy||5,000||$7.43||$37,150.00|| |
|7/20/2017||Sujal Shah||Insider||Buy||10,000||$7.34||$73,400.00|| |
|9/6/2016||Robert James Wills||Director||Buy||25,000||$2.43||$60,750.00|| |
|4/15/2016||Charles Mcwherter||VP||Buy||3,000||$1.68||$5,040.00|| |
|4/5/2016||Sujal Shah||CFO||Buy||55,000||$1.39||$76,450.00|| |
|4/4/2016||Sujal Shah||CFO||Buy||22,000||$1.39||$30,580.00|| |
|9/11/2015||Carl Goldfischer||Director||Sell||46,729||$2.74||$128,037.46|| |
|8/14/2015||Emster Kurt Von||Director||Buy||90,000||$2.69||$242,100.00|| |
|7/20/2015||Emster Kurt Von||Director||Buy||1,600,000||$2.81||$4,496,000.00|| |
|5/18/2015||Sujal Shah||CFO||Buy||10,000||$3.40||$34,000.00|| |
|5/18/2015||Wart Harold Van||CEO||Buy||7,500||$3.34||$25,050.00|| |
|5/15/2015||Charles Mcwherter||VP||Buy||2,000||$3.16||$6,320.00|| |
CymaBay Therapeutics (NASDAQ CBAY) News Headlines
|CymaBay Therapeutics Inc (CBAY) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - December 17 at 2:22 AM
|CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel - GlobeNewswire (press release)|
globenewswire.com - December 5 at 5:26 PM
|CymaBay Therapeutics, Inc. – Value Analysis (NASDAQ:CBAY) : December 4, 2017|
finance.yahoo.com - December 4 at 5:28 PM
|CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel|
finance.yahoo.com - December 4 at 9:15 AM
| Brokerages Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million|
www.americanbankingnews.com - December 2 at 10:51 AM
|CymaBay Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CBAY-US : December 1, 2017|
finance.yahoo.com - December 1 at 4:41 PM
|CymaBay Therapeutics Inc to Post FY2019 Earnings of ($1.13) Per Share, Leerink Swann Forecasts (CBAY)|
www.americanbankingnews.com - November 30 at 7:46 PM
|CymaBay Therapeutics (CBAY) Rating Reiterated by Leerink Swann|
www.americanbankingnews.com - November 29 at 1:48 PM
|CymaBay Therapeutics (CBAY) Given "Buy" Rating at HC Wainwright|
www.americanbankingnews.com - November 28 at 2:58 PM
|CymaBay Therapeutics Inc. (CBAY) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - November 22 at 1:34 AM
|FY2017 EPS Estimates for CymaBay Therapeutics Inc. (CBAY) Lowered by Analyst|
www.americanbankingnews.com - November 17 at 9:44 PM
|SunTrust Banks Comments on CymaBay Therapeutics Inc.'s Q1 2018 Earnings (CBAY)|
www.americanbankingnews.com - November 15 at 9:36 AM
|Kurt Von Emster Sells 50,048 Shares of CymaBay Therapeutics Inc. (CBAY) Stock|
www.americanbankingnews.com - November 14 at 8:05 PM
|CymaBay Therapeutics to Present at Three Investor Conferences|
finance.yahoo.com - November 13 at 11:29 PM
|Brokers Issue Forecasts for CymaBay Therapeutics Inc.'s FY2017 Earnings (CBAY)|
www.americanbankingnews.com - November 13 at 3:58 AM
|CymaBay Therapeutics Inc. (CBAY) Sees Large Growth in Short Interest|
www.americanbankingnews.com - November 13 at 2:32 AM
|Leerink Swann Comments on CymaBay Therapeutics Inc.'s Q1 2018 Earnings (CBAY)|
www.americanbankingnews.com - November 10 at 10:50 AM
|CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates - GlobeNewswire (press release)|
globenewswire.com - November 10 at 10:32 AM
|CymaBay Therapeutics' (CBAY) CEO Sujal Shah on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - November 9 at 1:02 AM
|Cantor Fitzgerald Reaffirms Buy Rating for CymaBay Therapeutics Inc. (CBAY)|
www.americanbankingnews.com - November 8 at 11:40 PM
|CymaBay Therapeutics, Inc. to Host Earnings Call|
finance.yahoo.com - November 8 at 8:00 PM
|CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates|
finance.yahoo.com - November 8 at 8:00 PM
|CymaBay Therapeutics Inc. (CBAY) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS|
www.americanbankingnews.com - November 8 at 7:56 PM
|CymaBay Therapeutics Inc. (CBAY) SVP Buys $43,350.00 in Stock|
www.americanbankingnews.com - November 6 at 9:50 PM
|CymaBay Therapeutics Inc. (CBAY) Director Carl Goldfischer Sells 18,000 Shares|
www.americanbankingnews.com - November 6 at 9:20 PM
|Kurt Von Emster Sells 59,209 Shares of CymaBay Therapeutics Inc. (CBAY) Stock|
www.americanbankingnews.com - November 1 at 5:44 PM
|CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8|
finance.yahoo.com - November 1 at 5:42 PM
|CymaBay Therapeutics Inc. (CBAY) to Release Quarterly Earnings on Tuesday|
www.americanbankingnews.com - October 31 at 8:08 AM
|CymaBay Therapeutics Inc. (CBAY) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - October 28 at 2:06 AM
|CymaBay Therapeutics Inc. (CBAY) Short Interest Up 35.5% in October|
www.americanbankingnews.com - October 28 at 1:26 AM
|Opinion: Harry Boxer's momentum stocks to watch this week - MarketWatch|
www.marketwatch.com - October 25 at 6:29 PM
|Harry Boxer’s momentum stocks to watch this week|
finance.yahoo.com - October 25 at 6:28 PM
|CymaBay to Host Post-AASLD Key Opinion Leader Meeting on ... - GlobeNewswire (press release)|
globenewswire.com - October 25 at 12:16 AM
|CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis|
finance.yahoo.com - October 23 at 8:49 PM
|CymaBay Therapeutics Inc. (CBAY) Sees Significant Increase in Short Interest|
www.americanbankingnews.com - October 14 at 2:04 AM
|CymaBay (CBAY) Announces Late-Breaking Presentation of Interim Results from Ongoing Phase 2 Study of Patients ... - StreetInsider.com|
www.streetinsider.com - October 10 at 6:11 PM
|CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting|
finance.yahoo.com - October 9 at 5:41 PM
|Contrasting CymaBay Therapeutics (CBAY) & Its Peers|
www.americanbankingnews.com - October 5 at 10:20 PM
|Your Daily Pharma Scoop: The First Trust NYSE Arca Biotechnology Index, Gilead's Single Pill, Acadia's New Trial|
seekingalpha.com - October 5 at 11:48 AM
|CymaBay Therapeutics Inc. (CBAY) Director Kurt Von Emster Sells 108,876 Shares|
www.americanbankingnews.com - October 4 at 7:40 PM
|CymaBay Therapeutics Inc. (CBAY) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - October 3 at 3:08 AM
|CymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 211,124 Shares|
www.americanbankingnews.com - October 2 at 7:16 PM
|CBAY Oct 2017 2.500 call|
finance.yahoo.com - September 30 at 1:05 PM
|CymaBay Therapeutics Inc. (CBAY) Given "Buy" Rating at Cantor Fitzgerald|
www.americanbankingnews.com - September 26 at 4:24 PM
|Cantor Fitzgerald Weighs in on CymaBay Therapeutics Inc.'s FY2017 Earnings (CBAY)|
www.americanbankingnews.com - September 22 at 7:22 AM
|Benzinga's Top Upgrades, Downgrades For September 20, 2017 - Benzinga|
www.benzinga.com - September 20 at 5:46 PM
|After-Hours Stock Movers 09/19: (KOOL) (GEMP) (CBAY) Higher; (BBBY) (IOVA) (ADBE) Lower (more...) - StreetInsider.com|
www.streetinsider.com - September 19 at 10:04 PM
|CymaBay Therapeutics Inc. (CBAY) Now Covered by Analysts at Cantor Fitzgerald|
www.americanbankingnews.com - September 19 at 5:48 PM
|Reviewing CymaBay Therapeutics (CBAY) & Its Peers|
www.americanbankingnews.com - September 18 at 6:23 PM
|CymaBay Therapeutics to Present at Two Investor Conferences|
finance.yahoo.com - September 18 at 5:17 PM
CymaBay Therapeutics (NASDAQ:CBAY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CymaBay Therapeutics (NASDAQ:CBAY) Income Statement, Balance Sheet and Cash Flow Statement
CymaBay Therapeutics (NASDAQ CBAY) Stock Chart for Sunday, December, 17, 2017